Pharmacokinetics of Continuous Infusion Fentanyl in Cancer Patients
Overview
- Phase
- Not Applicable
- Intervention
- fentanyl citrate
- Conditions
- Brain and Central Nervous System Tumors
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Enrollment
- 2
- Locations
- 1
- Primary Endpoint
- Pharmacokinetics of fentanyl citrate
- Status
- Terminated
- Last Updated
- 13 years ago
Overview
Brief Summary
RATIONALE: Studying blood samples from cancer patients undergoing pain treatment in the laboratory may help doctors learn more about how pain drugs work in the body. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at fentanyl in patients with cancer.
Detailed Description
OBJECTIVES: * To describe the pharmacokinetics of prolonged intravenous infusions of fentanyl citrate in adult patients with cancer. OUTLINE: Patients undergo blood sample collection before and after discontinuation of fentanyl citrate therapy (10 days total). Pharmacokinetic analysis is performed on the samples.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Cohort 1
receiving fentaly citrate
Intervention: fentanyl citrate
Cohort 1
receiving fentaly citrate
Intervention: pharmacological study
Outcomes
Primary Outcomes
Pharmacokinetics of fentanyl citrate
Time Frame: two baseline samples, serial samples obtained at 0,4,8,24,48,72,96,168,240 hrs after discontinuing fentanyl